Finland's Bioretec Q3 sales rise on repeat surgeon utilization, KOL network growth

Overview

• Finland medical device maker's Q3 net sales rose 85.5% yr/yr

• Adjusted sales margin improved to 68.7% from 59.4% yr/yr

• Q3 EBITDA loss narrowed slightly compared to last year

Outlook

• Company expects overall spending to remain stable and disciplined in the near term

• Company plans to introduce a new product every 12–18 months as part of its 2026–2028 strategy

• Company expects planned changes to generate annual cost savings of about EUR 0.3 mln

Result Drivers

• COMMERCIAL STRATEGY - Co said sales growth was driven by focused commercial strategy, including repeat surgeon utilization, KOL network, and selective distribution partnerships

• PRODUCT MIX - Improved adjusted sales margin attributed to sustained improvements in quality and mix of net sales

• NEW PRODUCT APPROVAL - FDA clearance for ActivaScrew Cannulated COM screw supported expansion of offering in U.S. market

Company press release:

Key Details

Analyst Coverage

• The one available analyst rating on the shares is "sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

• Wall Street's median 12-month price target for Bioretec Oy is €0.02, about 10.7% below its November 11 closing price of €0.02

Reuters Recommended Reads

• Nov 10 - Carlsmed Q3 sales jump 65% on surgeon user growth, raises FY revenue guidance

• Nov 10 - LENSAR Q3 revenue slightly misses estimates on slower surgical scheduling

• Nov 10 - Harvard Bioscience Q3 revenue rises 8%, beats estimates

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)